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ABstrAct
BAcKgrounD 
The prevalence of  metabolic syndrome (MS) is increasing worldwide, not sparing developing countries like Nigeria. 
Chronic kidney disease (CKD) is also assuming epidemic proportions globally. Metabolic syndrome has been associated 
with CKD in several reports, most of  which are foreign based. Given that data on CKD in MS patients is rare in this 
part of  the world, the study was undertaken with the aim of  determining the prevalence of  CKD in patients with MS.
MethoDs
Two hundred and twenty two subjects completed the study out of  the two hundred and thirty that met the criteria for 
MS as defined by the harmonized criteria for definition of  MS. CKD was defined as eGFR less than 60 ml/min/1.73 
m2 as determined by the Modification of  Diet for Renal Disease (MDRD) formula. Proteinuria was defined as presence 
of  at least 1+ of  protein in urine in absence of  leukocyturia or nitrituria.
results
Elevated blood pressure, elevated fasting glucose and central obesity were the commonest traits of  MS. The prevalence 
of  CKD in participants with MS was 20.3% while proteinuria was found in 121(54.5%) of  them. The prevalence of  
CKD increased with additional traits of  the syndrome.
conclusion
CKD and proteinuria are prevalent in patients with metabolic syndrome. Prevalence of  CKD in MS increases with 
additional component of  the syndrome.
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introDuction
The metabolic syndrome (MS) has evolved from a vague 
association of  common chronic diseases to a formally 
defined cluster of  clinical traits with adverse impact on 
cardiovascular risk. It may be characterized by abdominal 
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obesity, hyperglycaemia, hypertension, hypertryglyceridemia 
and reduced HDL cholesterol.
Several criteria have been put forward over time to aid 
in diagnosis of  this condition. These include those by 
the World Health organization (WHO),1 European 
Group for the Study of  Insulin resistance,2 the National 
Cholesterol Education Program Adult Treatment 
Panel (NCEP ATP) III,3 the American Association of  
Clinical Endocrinologists,4 the International Diabetes 
Federation(IDF) criteria.5 However in  October 2009, a 
joint statement was issued by the International Diabetes 
Federation; National Heart, Lung, and Blood Institute; 
American Heart Association; World Heart Federation; 
International Atherosclerosis Society; and International 
Association for the Study of  Obesity to standardize the 
diagnostic criteria for the metabolic syndrome.6 Agreed 
cut-points for all the components of  metabolic syndrome 
were published and the diagnosis defined as the presence 
of  any three or more abnormal findings: Elevated waist 
circumference(WC): population and country-specific; 
Serum triglycerides(TG) > 150mg/dl/ (1.7 mmol/l) or 
drug treatment for elevated triglycerides; Serum HDL 
cholesterol < 40mg/dl (1.0mmol/l) in men and < 50mg/dl 
(1.3mmol/l) in women or drug treatment for low HDL-C; 
Blood pressure > 130/85mmHg or drug treatment for 
elevated blood pressure(BP) and Fasting plasma glucose 
(FPG) >100mg/dl (5.6mmol/l) or drug treatment for 
elevated blood glucose.
About a quarter of  the world population is estimated 
to suffer from metabolic syndrome.7 Its prevalence in 
developing countries has been observed to be on the 
increase lately and this may be related to changes in lifestyle 
and diet.8,9 Although it is widely known that the metabolic 
syndrome is a major risk factor for the development of  
cardiovascular disease and type 2 diabetes, evidence linking 
MS with CKD has also emerged.10,11  CKD has become a 
major public health problem, with a growing burden and 
significant impact on morbidity, mortality, quality of  life, 
use of  health services and health expenditure. 
Mechanism by which the metabolic syndrome initiates 
or accelerates renal disease remains unclear but there are 
postulations that it may be related to the presence of  
obesity itself. Obesity has been shown to be an independent 
risk factor for CKD and has been associated with a type of  
focal segmental glomerulosclerosis called ‘obesity-related 
glomerulopathy.12 Insulin resistance may have a direct role 
in the pathogenesis of  renal injury, as a consequence of  
stimulating the sympathetic nervous system and renin-
angiotensin system.13 Dyslipidaemia, a feature of  the 
metabolic syndrome may induce toxic and inflammatory 
tubulo-interstitial injury.14 Treating end stage renal disease 
(ESRD) imposes a large economic burden on the patients, 
the health care delivery system and the society at large. 
Considering the magnitude of  the morbidity, mortality and 
huge cost of  management of  CKD and ESRD patients, it 
becomes imperative to adopt preventive strategies. Subjects 
with MS are thus candidates for CKD screening.
Studies on prevalence of  CKD in metabolic syndrome 
patients are rare in developing countries like Nigeria. The 
aim of  the study was to determine the prevalence of  CKD 
in patients with metabolic syndrome in Benin City, Nigeria.
MethoDs
The study was carried out in the University of  Benin 
Teaching Hospital (UBTH), a tertiary health care centre in 
Benin City. Benin City is an ancient city and a cosmopolitan 
town located in Edo State in the South-Southern geo-
political zone of  Nigeria. UBTH is a 600 bedded hospital 
and runs specialist hypertensive and diabetic clinics 
amongst other specialized services.
Consecutive hypertensive and diabetic patients attending 
the medical outpatient clinic of  UBTH from September 
2010 to May 2011 were screened for features of  MS as 
defined by the harmonized criteria for definition of  MS.6 
A WC cut off  of  94 cm for males and 80cm for females 
was used according to the current recommended threshold 
for abdominal obesity in Sub-Saharan Africa.6
Patients that had at least three of  the MS traits were 
recruited for the study. However, patients less than 18 years 
old, patients with CKD from other causes, apart from 
hypertension and diabetes,  pregnant women, HIV  patients 
and other wasting diseases, as well as patients with obvious 
ascites were excluded. Those with urinary tract infection as 
evidenced by leukocyturia or presence of  nitrites in urine 
were also excluded from the study.
The sample size was determined using the formula, 
N=Z2pq/d.2 15
Where N = minimum sample size, Z = normal standard 
deviate at 95% confidence Interval = 1.96, P = prevalence, 
q = 1-p, d = precision set at 0.05
In a study of  a group of  Nigerians with metabolic syndrome 
by Ulasi et al, the overall prevalence of  metabolic syndrome 
was 15.9%.16
Applying this as “p” in the Fischer’s formula, N=Z2pq/d2 
gives 205.
However, to make allowances for drop-outs, 230 patients 
with MS were enrolled.
Using interviewer – administered questionnaire, socio-
demographic data such as age, sex, marital status and 
ethnicity were obtained.
Blood pressure was taken using the Accoson mercury 
sphygmomanometer. For uniformity of  measurement, the 
first sound (Korotkoff  1) was taken as the systolic blood 
pressure and the extinction of  all sounds (Korotkoff  5) as 
the diastolic blood pressure. Blood pressure was recorded 
to the nearest 2mmHg. Elevated blood pressure as a 
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component of  MS was defined as BP of  130/85mmHg or 
use of  anti-hypertensives. [6]
Waist circumference (WC) was measured at a level midway 
between the lower rib margin and the iliac crest with the 
tape around the body in a horizontal position at the end of  
gentle expiration. Abdominal obesity was defined as waist 
circumferences of  > 80cm and > 94cm for females and 
males respectively.6
Mid-stream urine was collected and analyzed for proteinuria 
with a combi 9 dipstix. For the purpose of  this study, 
proteinuria was considered positive in the presence of  at least 
1+ of  protein in the absence of  leukocyturia or nitrituria. Six 
mls of  venous blood were collected from the participants 
and used for analysis of  urea and creatinine and serum lipid 
profile after an overnight fast. The abbreviated version of  the 
Modification of  Diet in Renal Disease (MDRD) equation17 
was used in estimating the glomerular filtration rate (GFR) 
viz: eGFR= 186.3x (serum creatinine) exp [-1.154] age exp 
[0.203] x [0.724 if  female] x (1.21 if  African). CKD was 
defined as eGFR< 60mls/min/1.73m.2
An HDL-C value of  less than 50mg/dl (1.3mmol/l) for 
females and 40mg/dl (1.0 mmol/l) for males was considered 
a significant component of  MS.6 For serum triglycerides, 
significantly elevated values were those > 150mg/dl.6 
FPG was determined using the accucheck glucometer and 
values > 100mg/dl considered elevated.6 Individuals who 
were already on medications for elevated blood glucose 
irrespective of  their present blood glucose readings were 
also enlisted.6
ethicAl consiDerAtion
Ethical approval was obtained from the Ethics and Research 
Committee of  UBTH before commencement of  the study. 
After a thorough explanation of  the details of  the study, the 
history to be obtained from participants as well as procedures 
to be performed, informed consent was obtained from those 
that were willing to partake in the study.
DAtA AnAlysis
Data was entered, stored and analyzed using the Statistical 
Package for Social Sciences for windows software version 
17.0 (SPSS Inc., Chicago, IL, USA). Continuous variables 
were presented as mean, standard deviation and range 
while categorical variables were presented as frequencies 
and percentages. Fisher’s exact test was used in testing 
for significant differences between groups. Results were 
presented in tabular forms. Confidence interval was at the 
95% limit and p values of  < 0.05 were accepted as being 
statistically significant.
results
A total of  five hundred and thirty hypertensive and diabetic 
patients were screened for metabolic syndrome. Out of  this, 
two hundred and thirty (43.4%) met the criteria for diagnosis 
of  the syndrome.  One hundred and sixty two of  those that 
met the criteria were females while sixty eight were males. 
There was no significant difference in the proportion of  
male and female subjects with MS (p = 0.572). However, 
eight patients did not have complete data. Two hundred and 
twenty two participants had complete data which were the 
ones used in analysis.
characteristics of  participants
Out of  the 222 participants that completed the study, 
64(28.8%) were males while 158(71.2%) were females.
The mean age of  the participants was 60.0+11.4 years. 
Majority (80.2%) of  them were married. Bini (54.5%) was 
the dominant tribe. The socio-demographic data of  the 
participants are shown in table1.
Two hundred and three (91.4%) patients were either known 
hypertensives or had BP> 130/85 on presentation. One 
hundred and ninety (85.6%) patients were either known 
diabetic patients or had an FPG > 100mg/dl (5.6 mmol/l). 
One hundred and seventy two (77.5%) participants had 
abdominal obesity. Ninety four (42.3%) participants either 
had TG > 50mg/dl (mmol/l) or were already on drug 
treatment for high TG while 117(52.7%) participants had low 
HDL or were on drug treatment for low HDL. Participants 
had various combinations of  these components ranging 
from three to all five.
prevalence of  cKD
The overall prevalence of  CKD in the study was 20.3%. The 
prevalence of  CKD in patients with 3, 4 and 5 MS traits 
were 15.3%, 27.0% and 40.0% respectively showing an 
increasing prevalence with an increasing number of  traits. 
This difference was observed to be statistically significant (P 
= 0.02) as reported in table 2.
Positive dipstick proteinuria was found in 121 (54.5%) of  the 
participants.
Discussion
Most of  the patients in this study were of  Edo State Origin 
(Bini and Esan). This is to be expected, considering that the 
hospital is located in Edo state. 
Among the five diagnostic traits for the metabolic syndrome, 
elevated blood pressure, hyperglycemia and abdominal 
obesity were the most prevalent in the patients. Similarly, 
these three traits were the most common components 
reported in Ervin’s report among metabolic syndrome 
cohorts in the US though obesity had the highest frequency in 
that report.18 Hypertriglyceridemia and low HDL cholesterol 
were the least frequent traits among the metabolic syndrome 
patients. This is in agreement with documented reports 
of  relatively low triglycerides and high HDL cholesterol 
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conc entrations especially among Africans.19, 20 In Ulasi’s 
series, hypertriglyceridemia was virtually non-existent in the 
patients.16
The prevalence of  CKD in the MS patients in this series 
was 20.3%. Unfortunately, there is a paucity of  data on 
prevalence rates of  CKD in MS patients to allow for 
adequate comparison with the findings from this study. 
However, Emem-Chioma et al  reported low prevalence 
rates of  CKD in MS patients of  4.8% in Rivers State, 
Nigeria, 21 This is markedly lower than the findings of  this 
study. Differing patient characteristics and methodology may 
have contributed to some of  the observed differences. Their 
population was younger and the sample size was smaller.  A 
Chinese study found a prevalence rate of  15.4% which is 
also less than the rate we found.22 Apart from possible ethnic 
and other demographic differences, the IDF criteria for MS 
was used in that study while we used the harmonized criteria.
Also, increased incidence rates of  CKD with increased 
odds have been reported severally in prospective studies of  
patients with MS compared with the normal population 10,23,24
There was a significant relationship between the number of  
components of  MS and CKD. The prevalence of  CKD was 
highest in those with all traits and least in those with only 
three components. Similar observations have been reported 
severally in literature.9, 10, 25 According to Lea of  the Emory 
University, the individual components of  the MS do not seem 
to have much effect on kidney disease progression but when 
taken together, the syndrome does seem to have a significant 
impact.26 There may thus be a synergistic effect among the 
various components in their association with CKD.
Over half  of  the patients had proteinuria. Although there 
was no control group for comparison, the prevalence of  
proteinuria in this study was indisputably high. Data in 
prevalence of  proteinuria in metabolic syndrome is also 
rare. Jutilainen et al found a high prevalence of  proteinuria 
in diabetic patients; 75.5% in men and 65.0% in women27 
Another Central African study reported a prevalence of  
23.8%.28 Even though only 5.7% of  Korean subjects with 
the metabolic syndrome had proteinuria, proteinuria was 
still more in metabolic syndrome patients compared with 
2.7% in patients without the syndrome.29 This low rate is 
however not in agreement with our findings. The reason for 
this difference is not clear but differences in demographic 
characteristics may also be contributory.
It is therefore likely from our study that metabolic syndrome 
has a positive association with renal disease. The exact 
mechanism by which the metabolic syndrome initiates or 
causes progression of  kidney disease remains unclear and 
is beyond the scope of  the study but may however warrant 
further studies.
This study had some limitations. Serum creatinine assay was 
not repeated for the patients during the study. Since accurate 
diagnosis of  CKD entails persistence of  abnormalities for at 
least 3 months, there may have been some over-estimation 
in this regard. In addition, diagnosing hyperglycaemia 
using a finger-prick glucose meter has limitations. Blood 
glucose meters measure the glucose in whole blood which 
is actually lower than plasma glucose. Fortunately however, 
the glucometer used in this study gave results in plasma 
equivalent.
Also, this study was a hospital based one where the 
sample tested were patients who were already attending a 
specialist clinic. A population based study where the general 
population is screened would probably have been more 
apt. Also, the cohort in our study was voluntary and could 
have been biased by the health worker effect. A younger 
population may probably have been more appropriate since 
older patients are more likely to have other co-morbidities, 
which themselves, predispose to CKD. Since women made 
up a vast majority of  the participants, there may be need for 
some caution in generalization of  results.
Despite the above limitations, the findings of  this study 
remain valid. The study has revealed a high prevalence of  
CKD in the metabolic syndrome which may be contributed 
to by a synergistic effect of  all the components of  the 
syndrome. There is therefore need for regular screening of  
patients with MS for CKD.
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Tables
Table 1:  Socio-demographic data of the MS patients 
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Table 2:  Relationship between number of metabolic syndrome traits and CKD
chronic kidney disease
no of   Ms
traits Yes No Total
3 22(15.3%) 122(84.7%) 144(100.0%)
4 17(27.0%) 46(73.0%) 63(100.0%)
5 6(40.0%) 9(60.0%) 15(100.0%)
Total 45(20.3%) 177(79.7%) 222(100.0%)
fisher’s exact p = 0.02
list of ABBreViAtion
ATP       Adult treatment panel
BP        Blood pressure
CKD       Chronic kidney disease
eGFR       Estimated glomerular filtration
ESRD       end stage renal disease
FPG       Fasting plasma glucose
HDL       High density lipoprotein
HDL-C      High density 
HIV       Human immunodeficiency virus Lipoprotein cholesterol
HTN       Hypertension
LDL       Low density lipoprotein
LDL-C      Low density lipoprotein Cholesterol
MDRD      `Modified diet in renal disease
MS        Metabolic syndrome
NCEP       National cholesterol education Program
TG       Triglyceride
UBTH       University of  Benin Teaching Hospital
WC       Waist circumference
